CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
CH Biotech R&D Co., Ltd. (6534) - Total Liabilities
Latest total liabilities as of September 2025: NT$1.06 Billion TWD
Based on the latest financial reports, CH Biotech R&D Co., Ltd. (6534) has total liabilities worth NT$1.06 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CH Biotech R&D Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how CH Biotech R&D Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CH Biotech R&D Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of CH Biotech R&D Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Barton Gold Holdings Ltd
AU:BGD
|
Australia | AU$14.80 Million |
|
TiumBio Co. Ltd
KQ:321550
|
Korea | ₩67.60 Billion |
|
Gamehost Inc
PINK:GHIFF
|
USA | $60.50 Million |
|
Circus SE
XETRA:CA1
|
Germany | €16.62 Million |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
Turkey | TL1.89 Billion |
|
Pharmosa Biopharm Inc.
TWO:6875
|
Taiwan | NT$225.10 Million |
|
Asia Plus Group Holdings PCL
BK:ASP
|
Thailand | ฿4.53 Billion |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
Germany | €210.36 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down CH Biotech R&D Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CH Biotech R&D Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CH Biotech R&D Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of CH Biotech R&D Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$982.44 Million | -12.99% |
| 2023-12-31 | NT$1.13 Billion | +1.94% |
| 2022-12-31 | NT$1.11 Billion | -15.16% |
| 2021-12-31 | NT$1.31 Billion | -6.71% |
| 2020-12-31 | NT$1.40 Billion | -- |